By Dean Seal
Anavex Life Sciences recorded a wider loss in its fiscal fourth quarter, though the shortfall was still smaller than analysts had been expecting.
The clinical-stage biopharmaceutical company posted a loss of $11.6 million for the three months ended Sept. 30 compared with a loss of $10.1 million in the same quarter a year ago.
Per share, the loss was 14 cents. Analysts polled by FactSet had been expecting a loss of 16 cents a share.
Overheads and R&D costs for the quarter were higher year-over-year, leaving the company with cash and cash equivalents of $132.2 million by quarter's end. The company said it is currently looking at about four years of runway at the current cash burn rate.
Shares rose 9.3% to $9.43 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 23, 2024 07:41 ET (12:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。